What our research found
The current SnagRx homepage, public plan flow, intake path, terms, refund policy, privacy policy, data-sharing opt-out, contact page, FDA compounding guidance, FDA dosing material, BBB profile, LegitScript checker, production AllyRx catalog, and internal affiliate record were checked. A synthetic, non-identifying intake profile was used only to inspect public eligibility logic. No name, email, phone number, payment, account, patient lead, or production data was submitted.
Modern Metabolic Medicine, Inc. is the legal operator named by SnagRx. The terms separate the consumer platform from OpenLoop Health, affiliated medical professional corporations and associations, individual clinicians, and dispensing pharmacies. The same operator also uses the Embody and RodeoMeds names, but SnagRx has its own domain, catalog, prices, support contact, checkout, and affiliate program, so it remains a distinct consumer review.
The contact page lists Modern Metabolic Medicine, Inc. at 1811 Silverside Road, Suite 260, Wilmington, Delaware 19180. BBB lists the same street and suite with ZIP code 19810. Because the provider's published ZIP is inconsistent with the city and the independent business profile, the draft preserves the conflict rather than silently correcting the provider.
The active primary catalog consists of compounded semaglutide and compounded tirzepatide weekly subcutaneous injections. Brand-name Wegovy, Ozempic, and Zepbound appear in regulatory or comparison language but are not separate products in the current public SnagRx checkout. They are therefore not treatment cards.
The public flow lists semaglutide at $99 billed for one month, $267 billed for three months, $474 billed for six months, and $828 billed for twelve months. Those totals equal $99, $89, $79, and $69 per month. The twelve-month rate requires the full $828 commitment.
The public flow lists tirzepatide at $149 billed for one month, $417 billed for three months, $774 billed for six months, and $1,428 billed for twelve months. Those totals equal $149, $139, $129, and $119 per month. The twelve-month rate requires the full $1,428 commitment.
The homepage calls the $69 and $119 headline figures a Labor Day promotion and shows a price-increase countdown. The embedded plan catalog labels its discount as continuing, but the campaign framing makes the durability of every term uncertain. The compact cards therefore use the one-month rates and remain comparison-ineligible until post-campaign prices are verified.
No separate membership fee is advertised. Current pages describe the selected price as including provider consultation, prescription when appropriate, medication, injection supplies, shipping, ongoing support, and written prescription access. Final compound concentration, additives, vial quantity, assigned pharmacy, and patient-specific rationale appear later.
The refund policy treats each multi-month purchase as one indivisible bundle rather than a month-to-month sequence. The intake consent separately says the subscription renews monthly, while the plan selector offers three-, six-, and twelve-month commitments. The exact post-term renewal amount and cadence should be saved from checkout before payment.
Most sales become final when payment is submitted. The policy denies refunds for unused or incomplete intake, missed consultation, a decision not to accept a prescription, unused service, unused months, and months in which medication was not shipped or services were not used.
The stated exception is clinician-determined medical disqualification. Any unused-portion refund may be reduced for live or asynchronous consultation, provider review, records or laboratory work, prescriptions, and medication already dispensed or shipped. Prescription products are nonreturnable; damaged or incorrect products may be replaced rather than refunded.
Cancellation can be requested through the portal, email, or phone. The refund policy requires at least 72 hours before the next billing date to avoid another nonrefundable charge. Access continues through the already paid term.
The intake begins with a roughly five-minute medical qualifier. Payment precedes final provider review and any prescription. SnagRx says review usually occurs within 24 hours and often within five hours, but this is a provider-stated service target, not a guarantee.
The homepage FAQ says SnagRx is available in every state except Louisiana and requires age 19 or older in Nebraska. The intake contains explicit disqualification paths for Louisiana and Nebraska applicants under 19. The terms instead say the service is available in all 50 states and the District of Columbia, subject to service-specific limits. Operational FAQ and intake controls support excluding Louisiana while the conflict remains.
The terms name Red Rock Compounding Pharmacy in Utah, Health Warehouse in Kentucky, Precision Medicine in New York, and Triad Rx in Alabama. Prescriptions may transfer among pharmacies for availability, pricing, or operations, and patient pharmacy choice is allowed where applicable. SnagRx says its partners are U.S. 503A pharmacies, but the assigned pharmacy and exact prescription remain patient-specific.
SnagRx says prescriptions received before 2 p.m. Central Time ship the same day, use next-day UPS in temperature-controlled packaging, and ship Monday when received Friday through Sunday. Other homepage copy describes delivery in one to two days. The terms correctly frame all timing as an estimate affected by pharmacy processing, verification, carriers, weather, holidays, storage, and state requirements.
Support is available through the patient portal, hello@snagrx.com, and (469) 459-3723. The site advertises 24/7 support and says the contact route reaches a real person, but no universal response-time or urgent clinical, pharmacy, billing, and shipment escalation standard is published.
A homepage FAQ lists semaglutide at 0.25 mg weekly for four weeks and 0.5 mg for the next eight weeks. The same FAQ says tirzepatide starts at 10/mg and increases to 20/mg, an apparent unit or dose error. A separate returning-patient selector lists tirzepatide strengths from 2.5 to 15 mg. The draft does not repeat the erroneous line as medical guidance.
The semaglutide FAQ also says dosage will include ondansetron, but does not establish whether it is routinely combined, separately prescribed, optional, or included in the dispensed compound. Intake labels such as muscle support, nausea support, energy, sleep, mental clarity, hormones, and longevity disclose no corresponding active ingredients. None becomes a separate therapy.
FDA says compounded semaglutide and tirzepatide are not FDA approved and are not reviewed before marketing for safety, effectiveness, or quality. FDA also warns that milligram, milliliter, and unit confusion, variable concentrations, doses beyond approved labels, and accelerated titration have led to serious adverse events. Exact label and clinician instructions are essential.
SnagRx uses wording about the same medications people discuss and compounds produced in FDA-regulated facilities. FDA specifically warns telehealth marketers not to describe a compound as the same as an approved medicine or as sourced from an FDA-approved or FDA-licensed facility, because FDA does not approve or license compounding facilities.
The public flow contains post-purchase upsells for NAD+, glutathione, and sermorelin and an optional SnagRx VIP+ discount membership. They are not part of the primary pre-purchase GLP-1 catalog. Exact formulation, route for every item, supply quantity, laboratory requirements, and reusable catalog matches were not sufficiently established, so they remain editorial-only.
The privacy policy describes collection and sharing of identifiers, health information, payment data, device data, cookies, and usage data with clinicians, pharmacies, service providers, affiliates, analytics, and advertising partners. The opt-out page says some cross-site targeted-ad sharing may qualify as a sale or sharing under state law. It honors Global Privacy Control where required.
The intake states that information is never shared and is protected by HIPAA. That absolute wording is difficult to reconcile with the privacy and opt-out pages, which describe operational and advertising disclosures. The policy also warns that protected health information stored on a mobile device may be unencrypted. Consumers should review both documents rather than relying on the intake assurance alone.
At the research cutoff, BBB displayed an F rating for Modern Metabolic Medicine, Inc., said the business was not accredited, and cited failure to respond to 28 complaints. BBB complaint data is not a clinical-quality measure and changes over time, but the operator-level support and fulfillment signal is material because the profile identifies SnagRx, Embody, and RodeoMeds as alternate names.
SnagRx displays a LegitScript seal linked to LegitScript's official domain checker. The checker required reCAPTCHA and did not return a status in the accessible public session, so independent confirmation of the certification was inconclusive. The draft records the provider's claim without presenting the seal as verified.
The strongest features are an easy-to-scan two-product catalog, visible term totals, named clinical and pharmacy roles, no separate membership fee, and detailed shipping promises. The weakest are promotional price uncertainty, severe refund limits, renewal and state conflicts, dosing and FDA-marketing problems, privacy inconsistency, and recent operator-level complaint handling.
- Primary treatment is limited to compounded semaglutide and compounded tirzepatide weekly injections.
- One-month prices are $99 and $149; the $69 and $119 headlines require twelve-month prepayment during a temporary campaign.
- Most sales are final at payment, including unused months and several incomplete-care scenarios.
- The public tirzepatide FAQ contains an apparent unit error and conflicts with a separate dose selector.
- State availability, renewal cadence, and privacy language conflict across current public surfaces.
- Post-purchase NAD+, glutathione, sermorelin, and benefit labels are not turned into primary therapy cards.
